

"Express Mail" Label No. EV 33210648245
Date of Deposit 12/29/03

PATENT
Attorney Docket No.: 015280-342100US
Client Ref. No.: E-019-98/1
Customer No.: 20350

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop PCT
Commissioner for Patents

P.O. Box 1450
Alexandria, VA 22313-1450

By: [Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KASLOW *et al.*

Application No.: 09/554,960

Filed: February 12, 2003

For: VACCINES FOR BLOCKING
TRANSMISSION OF *Plasmodium vivax*

Confirmation No.: 6829

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Attn: Ms. Vonda M. Wallace
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notification of Defective Response mailed September 16, 2003, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Appl. No. 09/554,960

Amdt. December 23, 2003

Reply to Notification of Defective Response of September 16, 2003

PATENT

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 8 of this paper.

Remarks begin on page 14 of this paper.